secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0000950170-24-117568
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint reports positive Phase 2 VERONA interim data for DURAVYU in DME; +8.9 letters BCVA
--------------------------------------------------------------------------------

- DURAVYU 2.7mg showed +8.9 letter improvement in BCVA vs +3.2 for aflibercept control at 16 weeks.
- CST reduction of 68.1 microns vs 30.5 microns for control.
- 82% of DURAVYU 2.7mg eyes were supplement-free vs 50% for control at 16 weeks.
- No DURAVYU-related ocular or systemic SAEs reported; no endophthalmitis, vasculitis, or IOI.
- Full topline data from VERONA expected in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/0000950170-24-117568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017024117568/eypt-20241028.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-117568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer